The treatment results in a significant reduction in ovarian tumor volume and weight. It downregulates Ki67, TGF‐β, and PI3K, and inhibits Akt phosphorylation. Additionally, there is a reduction in JAK expression, STAT3 phosphorylation, and IL‐6 concentrations. Proliferation is inhibited through the downregulation of the PI3K/Akt and JAK/STAT3 signaling pathways. This evidence concerns the gene AKT1 and ovarian neoplasm.